News

Based on the growth of the clinical research market and the demand for outsourced eClinical services, unithink claimed that it has increased its operations by 50% in the

Akebia is expected to recruit up to 28 patients in AKB-6548 Phase 2a study, to assess the safety, tolerability and pharmacokinetics of a single dose of AKB-6548 in

NovaBay Pharma’s dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or

Under this licence, Mesoblast will now make MPC products commercially available to doctors and hospitals across Australia for a patient’s own, or autologous, use in the repair and

The vaccine has been developed to prevent or delay the recurrence sarcoma at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development completed in 2009. MabVax

GSK stated that the post-marketing study is designed to examine the comparative cardiovascular safety of Rosiglitazone (Avandia) and Pioglitazone (Actos) in patients with type 2 diabetes which was

Gilead Sciences has posted a net income of $712.1m for the second quarter 2010, or $0.79 per diluted share, compared to $571.4m, or $0.61 per diluted share, for

SiDMAP and Roche have presented the results of the study, entitled ‘A Novel Approach for the Treatment of Type 2 Diabetes (T2D): Characterisation of a Potent, Orally Active,

Tibotec said that TMC278 is an investigational product, and the safety and efficacy has not yet been established. Echo (TMC278-TiDP6-C209) and Thrive (TMC278-TiDP6-C215) are pivotal Phase 3, double-blind,